BeyondSpring's Next Move Uncertain After Plinabulin CRL
Limited Impact On China Partner Hengrui?
Executive Summary
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.
You may also be interested in...
Finance Watch: SPACs Lose Their Luster As Difficulties Mount
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.
Hunger Game: Hengrui Hunts New Cancer Drug With $200m BeyondSpring Tie-up
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.
China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.